Hydroxocobalamin Injection Shortage: FDA Update
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Hydroxocobalamin Injection is currently in shortage, with the only manufacturer reporting it as unavailable until June 2026, affecting patients who depend on this medication.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 8, 2026 and geographically references United States. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Hydroxocobalamin Injection.
What's in Shortage
The generic drug Hydroxocobalamin Injection, also known by the brand name HYDROXOCOBALAMIN, is currently in shortage. It is an injection dosage form, and its status is listed as current. The therapeutic category is 'Other'. This shortage was first posted on 11/04/2024 and last updated on 04/01/2026.
Which Manufacturers Are Affected
Teva Pharmaceuticals USA, Inc. is the affected manufacturer, with the drug unavailable. Estimated recovery is June 2026. The presentation is Hydroxocobalamin, Injection, 1000 MCG/ML, 30 ML Multi-Dose Vial (NDC 0591-2888-30). For inquiries, their contact information is 800-545-8800.
Why There's a Shortage
The reason for the shortage is listed as 'Other'. No additional details were provided.
What Patients Should Do
Patients who rely on this medication should talk to their pharmacist or healthcare provider to discuss the shortage and explore options. They can also contact the manufacturer for more information. Please remember that patients should always consult their healthcare provider for any guidance on their treatment, as this article does not provide medical advice.
Source
This information is attributed to the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,228 characters here).
Similar severity timing
Same severity (high) notices issued closest in time to April 8, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.